home / stock / cyth / cyth quote
Last: | $1.40 |
---|---|
Change Percent: | 1.38% |
Open: | $1.3511 |
Close: | $1.40 |
High: | $1.4 |
Low: | $1.33 |
Volume: | 21,590 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.4 | $1.3511 | $1.4 | $1.4 | $1.33 | 21,590 | 05-17-2024 |
$1.37 | $1.41 | $1.37 | $1.44 | $1.35 | 52,854 | 05-16-2024 |
$1.43 | $1.47 | $1.43 | $1.47 | $1.4 | 16,340 | 05-15-2024 |
$1.41 | $1.4 | $1.41 | $1.5372 | $1.4 | 32,013 | 05-14-2024 |
$1.4 | $1.45 | $1.4 | $1.4883 | $1.4 | 20,592 | 05-13-2024 |
$1.47 | $1.51 | $1.47 | $1.55 | $1.45 | 34,534 | 05-10-2024 |
$1.45 | $1.55 | $1.45 | $1.59 | $1.44 | 75,625 | 05-09-2024 |
$1.5 | $1.53 | $1.5 | $1.5526 | $1.49 | 18,777 | 05-08-2024 |
$1.51 | $1.51 | $1.51 | $1.58 | $1.501 | 26,280 | 05-07-2024 |
$1.53 | $1.56 | $1.53 | $1.6199 | $1.5 | 32,025 | 05-06-2024 |
$1.51 | $1.5 | $1.51 | $1.55 | $1.48 | 26,352 | 05-03-2024 |
$1.47 | $1.46 | $1.47 | $1.5 | $1.45 | 19,103 | 05-02-2024 |
$1.45 | $1.53 | $1.45 | $1.57 | $1.45 | 29,137 | 05-01-2024 |
$1.46 | $1.45 | $1.46 | $1.4799 | $1.3511 | 32,673 | 04-30-2024 |
$1.47 | $1.32 | $1.47 | $1.47 | $1.2831 | 56,557 | 04-29-2024 |
$1.26 | $1.33 | $1.26 | $1.35 | $1.26 | 28,155 | 04-26-2024 |
$1.29 | $1.285 | $1.29 | $1.31 | $1.27 | 16,858 | 04-25-2024 |
$1.3 | $1.23 | $1.3 | $1.31 | $1.22 | 20,966 | 04-24-2024 |
$1.21 | $1.24 | $1.21 | $1.28 | $1.2 | 33,064 | 04-23-2024 |
$1.26 | $1.2 | $1.26 | $1.32 | $1.17 | 84,156 | 04-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
Cyclo Therapeutics Inc. Company Name:
CYTH Stock Symbol:
NASDAQ Market:
Ongoing progress toward last patient enrolled in pivotal Phase 3 study (“TransportNPC™”) evaluating Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1), expected Q2 2024 Topline data from 48-week interim analysis expected H1 2025...
Continued progress of pivotal Phase 3 study (TransportNPC™) evaluating Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) toward 48-week comparative interim analysis data readout, planned for Q1 2025 Aligned development strategy for Trappsol ...